☆ 4.7 Article

Cefiderocol activity is compromised by acquired extended-spectrum oxacillinases in Pseudomonas aeruginosa

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2023)

Related references

Note: Only part of the references are listed.

Article Infectious Diseases

In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii

Christian M. Gill et al.

Summary: The in vivo efficacy and resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam and meropenem were evaluated using human-simulated regimens in a murine infection model. The combinations showed significant kill against cefiderocol-non-susceptible isolates and prevented resistance development during treatment against cefiderocol-high-end-susceptible isolates.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Add to Collection

Article Infectious Diseases

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)

Mical Paul et al.

Summary: These guidelines address the targeted antibiotic treatment of 3GCephRE and carbapenem-resistant Gram-negative bacteria, focusing on the effectiveness of individual antibiotics and on combination versus monotherapy. Most recommendations are based on low-certainty evidence.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

Add to Collection

Article Microbiology

Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa

Laurent Poirel et al.

Summary: The study evaluated the susceptibility of broad-spectrum beta-lactamases to various antibiotics, and found that clavulanic-acid-inhibited extended-spectrum beta-lactamases significantly affected the susceptibility to ceftazidime-avibactam, ceftolozane-tazobactam, and cefiderocol.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Add to Collection

Article Immunology

Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)

Pranita D. Tamma et al.

Summary: This article provides updated guidance on the treatment of infections caused by ESBL-E, CRE, and DTR-P. aeruginosa. The guidance was developed by a panel of infectious diseases specialists and includes preferred and alternative treatment recommendations. The document emphasizes the importance of consulting with an infectious diseases specialist for the treatment of antimicrobial-resistant infections.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Infectious Diseases

Characterisation of cefiderocol-non-susceptible Acinetobacter baumannii isolates from Taiwan

Yoshinori Yamano et al.

Summary: This study conducted in Taiwan demonstrated that the addition of avibactam could significantly decrease the minimum inhibitory concentration of CFDC-non-susceptible CRAB isolates, indicating the involvement of beta-lactamases in resistance.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2022)

Add to Collection

Article Infectious Diseases

Evolution of β-lactamase-mediated cefiderocol resistance

Christopher Frohlich et al.

Summary: This study investigated the impact of cefiderocol on resistance development and the evolution of beta-lactamases from different Ambler classes. The expression of bla(KPC-2), bla(CMY-2), bla(CTX-M-15), and bla(NDM-1) significantly reduced cefiderocol susceptibility, while mutations in these enzymes further increased cefiderocol resistance. Resistance development also led to collateral changes in sensitivity to other beta-lactam drugs and functional trade-offs.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Add to Collection

Article Infectious Diseases

Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa

Cristina Lasarte-Monterrubio et al.

Summary: This study evaluated the activity of new drugs against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa isolates. Cefiderocol and cefepime/taniborbactam were the most active agents. However, resistance was observed in some strains with specific mutations or overexpression of efflux pumps.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Add to Collection

Article Microbiology

Functional and Structural Characterization of OXA-935, a Novel OXA-10-Family β-Lactamase from Pseudomonas aeruginosa

Nathan B. Pincus et al.

Summary: Resistance to antipseudomonal penicillins and cephalosporins in Pseudomonas aeruginosa is often driven by the overproduction of AmpC beta-lactamase and OXA-10-family beta-lactamases. This study identified a novel allele of bla(OX)(A-10), named bla(OX)(A-935), which confers ceftazidime resistance and showed increased catalytic efficiency for ceftazidime compared to OXA-14. Crystal structures of OXA-14 and OXA-935 revealed that the F153S mutation in OXA-935 increases flexibility in the omega loop. Considering the reliance on novel beta-lactam/beta-lactamase inhibitor combinations, the amino acid changes in OXA-10-family beta-lactamases are of concern.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Add to Collection

Article Infectious Diseases

Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections

Jorge Arca-Suarez et al.

Summary: This study identified that alterations in OXA-10 are involved in the development of resistance to cephalosporin/β-lactamase inhibitor combinations in P. aeruginosa during treatment.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

Add to Collection

Article Microbiology

Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study

Damien Fournier et al.

Summary: This study evaluated the resistance mechanisms of Pseudomonas aeruginosa to ceftolozane/tazobactam, identifying strains with various resistance genes and high production of cephalosporinase PDC. It also found mutations in regulatory genes and enzymes contributing to resistance, highlighting the importance of both intrinsic and transferable mechanisms in C/T-resistant P. aeruginosa.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Microbiology

Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii

Laurent Poirel et al.

Summary: The study found that PER-like beta-lactamases and NDM-like beta-lactamases significantly contributed to reduced susceptibility to Cefiderocol (FDC). The combination of FDC with avibactam exhibited excellent activity against multidrug-resistant isolates coproducing OXA-23 and PER-type beta-lactamases.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Infectious Diseases

Stability and low induction propensity of cefiderocol against chromosomal AmpC beta-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae

Akinobu Ito et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)

Add to Collection

Letter Infectious Diseases

Stability of cefiderocol against clinically significant broad-spectrum oxacillinases

Laurent Poirel et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)

Add to Collection

Article Microbiology

In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria

Akinobu Ito et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)

Add to Collection

Review Microbiology

The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria

Xian-Zhi Li et al.

CLINICAL MICROBIOLOGY REVIEWS (2015)

Add to Collection

Article Microbiology

Class D β-Lactamases: Are They All Carbapenemases?

Nuno T. Antunes et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)

Add to Collection

Article Microbiology

Structures of the Class D Carbapenemases OXA-23 and OXA-146: Mechanistic Basis of Activity against Carbapenems, Extended-Spectrum Cephalosporins, and Aztreonam

Kip-Chumba J. Kaitany et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)

Add to Collection

Article Infectious Diseases

Ceftazidime-hydrolysing β-lactamase OXA-145 with impaired hydrolysis of penicillins in Pseudomonas aeruginosa

Didier Hocquet et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)

Add to Collection

Article Microbiology

Crystal Structure of the Narrow-Spectrum OXA-46 Class D β-Lactamase: Relationship between Active-Site Lysine Carbamylation and Inhibition by Polycarboxylates

Jean-Denis Docquier et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)

Add to Collection

Article Biochemistry & Molecular Biology

Critical Role of Tryptophan 154 for the Activity and Stability of Class D β-Lactamases

Stephane Baurin et al.

BIOCHEMISTRY (2009)

Add to Collection

Article Infectious Diseases

In vivo selection of oxacillinase-mediated ceftazidime resistance in Pseudomonas aeruginosa

S Leotard et al.

MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.